Cardiovascular biomarkers: the state of the art in 2006.
BACKGROUND
The explosion in cardiovascular biomarkers has been stimulated in large part by proteomics, genomics and an improved understanding of the pathophysiology of cardiovascular disease. New advances are occurring rapidly and remaining on the cutting edge of the science is harder and harder. In the past few years, major changes have evolved in our ability to use cardiac troponin, BNP and CRP which will markedly impact on their clinical utility. These changes including greater sensitivity, a better understanding of what specific fragments are being measured and how these markers are used clinically is obligatory. There is also a need for new markers.


CONCLUSIONS
As with other disciplines, this work has built on the work of others.
Jaffe
Allan S
AS
Cardiology and Laboratory Medicine, Mayo Clinic, Rochester, Minnesota 55905, United States. Jaffe.Allan@Mayo.edu
D000818:Animals; D015415:Biomarkers / Q000032:analysis*; D002097:C-Reactive Protein / Q000032:analysis; D002318:Cardiovascular Diseases / Q000175:diagnosis* / Q000378:metabolism; D006801:Humans; D020097:Natriuretic Peptide, Brain / Q000032:analysis; D014336:Troponin / Q000097:blood
D015415:Biomarkers; D014336:Troponin; D020097:Natriuretic Peptide, Brain; D002097:C-Reactive Protein